Investing.com - Biomarin Pharma reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $-0.32 on revenue of $449.81M. Analysts polled by Investing.com EPS of $-0.36 on revenue of $442.09M.
Biomarin Pharma 's are up 2% and is trading at $82.52 , still down 12.40% from its 52 week high of $94.20 set on Thursday, February 10, 2022.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on Tuesday, January 25, 2022, who reported EPS of $2.13 on revenue of $24.8B, EPS of $2.12 on revenue of $25.28B.
Roche Holding ADR had matched expectations on Thursday, February 3, 2022 with fourth quarter EPS of $1.29 on revenue of $17.54B, for EPS of $1.29 on revenue of $17.1B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar